A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS.
Smith KER, et al.
Front Immunol. 2023 Oct 31;14:1279387. doi: 10.3389/fimmu.2023.1279387. eCollection 2023.
Front Immunol. 2023.
PMID: 38022659
Free PMC article.
Clinical Trial.
INTRODUCTION: Metastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). ...Median follow up was 19.1 months. 4 dose levels (DLs) were evaluate …
INTRODUCTION: Metastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically …